endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.15829/2713-0177-2023-6OVSNAJendofocus-6Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWСиндром гиперкальциемии: дифференциально-диагностический поиск и тактика леченияHypercalcemia syndrome: differential diagnostic search and treatment tacticshttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.DemidovaT. Yu.

д.м.н., профессор, зав. кафедрой эндокринологии лечебного факультета

Москва

Moscow

https://orcid.org/0000-0002-3656-0312ЛобановаК. Г.LobanovaK. G.

ассистент кафедры эндокринологии лечебного факультета

Москва

Moscow

miss.sapog@mail.ruhttps://orcid.org/0000-0002-3684-9992КоротковаТ. Н.KorotkovaT. N.

зав. лабораторией клинической биохимии, иммунологии и аллергологии

Москва

Moscow

ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава РоссииPirogov Russian National Research Medical UniversityФГБУН Федеральный исследовательский центр питания, биотехнологии и безопасности пищиFederal Research Center for Nutrition, Biotechnology and Food Safety20231005202341Коморбидность6677Copyright © Демидова Т.Ю., Лобанова К.Г., Короткова Т.Н., 20232023Демидова Т.Ю., Лобанова К.Г., Короткова Т.Н.Demidova T.Y., Lobanova K.G., Korotkova T.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/6

Гиперкальциемия является частой лабораторной находкой. Наиболее распространенными причинами высокого кальция в крови являются первичный гиперпаратиреоз, третичный гиперпаратиреоз, рак околощитовидных желез, злокачественные новообразования, длительная терапия препаратами лития и тиазидными диуретиками, интоксикация витамином D, требующие совершенно разного подхода к лечению. Именно поэтому врачу-клиницисту важно уметь проводить дифференциально-диагностический поиск синдрома гиперкальциемии для того, чтобы установить причину высокого кальция в крови и определить верную тактику ведения пациентов.

Hypercalcemia is a common laboratory finding. The most common causes of high blood calcium are primary hyperparathyroidism, tertiary hyperparathyroidism, parathyroid cancer, malignant neoplasms, long-term therapy with lithium and thiazide diuretics, vitamin D intoxication, which require a different approach to treatment. Therefore, it is important for a doctor to be able to conduct a differential diagnostic search for hypercalcemia syndrome in order to establish the cause of high blood calcium and determine the correct tactics for managing patients.

гиперкальциемиябисфосфонатыденосумабпервичный гиперпаратиреоззлокачественные новообразованияhypercalcemiabisphosphonatesdenosumabprimary hyperparathyroidismmalignancyReferencesTinawi M. Disorders of Calcium Metabolism: Hypocalcemia and Hypercalcemia. Cureus. 2021;13(1):e12420. doi:10.7759/cureus.12420.Tinawi M. Disorders of Calcium Metabolism: Hypocalcemia and Hypercalcemia. Cureus. 2021;13(1):e12420. doi:10.7759/cureus.12420.Tonon C, Silva T, Pereira F, et al. A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia. Med Sci Monit. 2022;28:e935821. doi:10.12659/MSM.935821.Tonon C, Silva T, Pereira F, et al. A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia. Med Sci Monit. 2022;28:e935821. doi:10.12659/MSM.935821.Ахполова В. О., Брин В. Б. Обмен кальция и его гормональная регуляция. Журнал фундаментальной медицины и биологии. 2017;2:38-46.Akhpolova VO, Brin VB. Calcium metabolism and its hormonal regulation. Journal of Fundamental Medicine and Biology. 2017;2:38-46. (In Russ.)Мокрышева Н. Г., Еремкина А. К., Мирная С. С. и др. Клинические рекомендации по первичному гиперпаратиреозу, краткая версия. Проблемы Эндокринологии. 2021;67(4):94-124. doi:10.14341/probl12801.Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.) doi:10.14341/probl12801.Charoenngam N, Shirvani A, Holick MF. Vitamin D for skeletal and non-skeletal health: What we should know. J Clin Orthop Trauma. 2019;10(6):1082-93. doi:10.1016/j.jcot.2019.07.004.Charoenngam N, Shirvani A, Holick MF. Vitamin D for skeletal and non-skeletal health: What we should know. J Clin Orthop Trauma. 2019;10(6):1082-93. doi:10.1016/j.jcot.2019.07.004.Hands JM, Moy LS. Calcium: More Than Bone? Implications for Clinical Practice and Theory. J Clin Med Res. 2021;13(5):253-7. doi:10.14740/jocmr4505.Hands JM, Moy LS. Calcium: More Than Bone? Implications for Clinical Practice and Theory. J Clin Med Res. 2021;13(5):253-7. doi:10.14740/jocmr4505.Srinivasan A, Wong FK, Karponis D. Calcitonin: A useful old friend. J Musculoskelet Neuronal Interact. 2020;20(4):600-9.Srinivasan A, Wong FK, Karponis D. Calcitonin: A useful old friend. J Musculoskelet Neuronal Interact. 2020;20(4):600-9.Sulaiman S, Mukherjee S, Sharma S, et al. Prevalence and Etiological Profile of Hypercalcemia in Hospitalized Adult Patients and Association with Mortality. Indian J Endocrinol Metab. 2022;26(5):453-8. doi:10.4103/ijem.ijem_223_21.Sulaiman S, Mukherjee S, Sharma S, et al. Prevalence and Etiological Profile of Hypercalcemia in Hospitalized Adult Patients and Association with Mortality. Indian J Endocrinol Metab. 2022;26(5):453-8. doi:10.4103/ijem.ijem_223_21.Gallagher JC, Smith LM, Yalamanchili V. Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women. Menopause. 2014;21(11):1173-80. doi:10.1097/GME.0000000000000270.Gallagher JC, Smith LM, Yalamanchili V. Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women. Menopause. 2014;21(11):1173-80. doi:10.1097/GME.0000000000000270.Banu S, Batool S, Sattar S, et al. Malignant and Non-Malignant Causes of Hypercalcemia: A Retrospective Study at a Tertiary Care Hospital in Pakistan. Cureus. 2021;13(6):e15845. doi:10.7759/cureus.15845.Banu S, Batool S, Sattar S, et al. Malignant and Non-Malignant Causes of Hypercalcemia: A Retrospective Study at a Tertiary Care Hospital in Pakistan. Cureus. 2021;13(6):e15845. doi:10.7759/cureus.15845.Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. Rare Causes of Hypercalcemia: 2021 Update. J Clin Endocrinol Metab. 2021;106(11):3113-28. doi:10.1210/clinem/dgab504.Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. Rare Causes of Hypercalcemia: 2021 Update. J Clin Endocrinol Metab. 2021;106(11):3113-28. doi:10.1210/clinem/dgab504.Lee CT, Yang CC, Lam KK, et al. Hypercalcemia in the emergency department. Am J Med Sci. 2006;331(3):119-23. doi:10.1097/00000441-200603000-00002.Lee CT, Yang CC, Lam KK, et al. Hypercalcemia in the emergency department. Am J Med Sci. 2006;331(3):119-23. doi:10.1097/00000441-200603000-00002.Majety P, Groysman A, Erlikh N, et al. Predictors of Mortality in Hypercalcemia of Advanced Chronic Liver Disease. Endocr Pract. 2022;28(10):1062-8. doi:10.1016/j.eprac.2022.07.008.Majety P, Groysman A, Erlikh N, et al. Predictors of Mortality in Hypercalcemia of Advanced Chronic Liver Disease. Endocr Pract. 2022;28(10):1062-8. doi:10.1016/j.eprac.2022.07.008.Баранова И. А., Зыкова Т. А. Нормокальциемический первичный гиперпаратиреоз — "новая эра" в диагностике старого заболевания. Проблемы эндокринологии. 2017;63(4):236-44. doi:10.14341/probl2017634236-244.Baranova IA, Zykova TA. Normocalcemic primary hyperparathyroidism — "new era" in diagnosis of an old disease. Problemy Endokrinologii. 2017;63(4):236-44. (In Russ.) doi:10.14341/probl2017634236-244.Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg. 2009;33(11):2314-23. doi:10.1007/s00268-009-9942-4.Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg. 2009;33(11):2314-23. doi:10.1007/s00268-009-9942-4.Dorflinger C, Fuller M. Lithium-induced hypercalcemia with normal parathyroid hormone: A case report. Ment Health Clin. 2019;9(5):318-21. doi:10.9740/mhc.2019.09.318.Dorflinger C, Fuller M. Lithium-induced hypercalcemia with normal parathyroid hormone: A case report. Ment Health Clin. 2019;9(5):318-21. doi:10.9740/mhc.2019.09.318.Meehan AD, Udumyan R, Kardell M, et al. Lithium-associated hypercalcemia: pathophysiology, prevalence, management. World J Surg. 2018;42(2):415-24. doi:10.1007/s00268-017-4328-5.Meehan AD, Udumyan R, Kardell M, et al. Lithium-associated hypercalcemia: pathophysiology, prevalence, management. World J Surg. 2018;42(2):415-24. doi:10.1007/s00268-017-4328-5.Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. J Clin Endocrinol Metab. 2016;101(3):1166-73. doi:10.1210/jc.2015-3964.Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. J Clin Endocrinol Metab. 2016;101(3):1166-73. doi:10.1210/jc.2015-3964.Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab. 2018;32(5):609-19. doi:10.1016/j.beem.2018.05.004.Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab. 2018;32(5):609-19. doi:10.1016/j.beem.2018.05.004.Palumbo VD, Palumbo VD, Damiano G, et al. Tertiary hyperparathyroidism: a review. Clin Ter. 2021;172(3):241-6. doi:10.7417/CT.2021.2322.Palumbo VD, Palumbo VD, Damiano G, et al. Tertiary hyperparathyroidism: a review. Clin Ter. 2021;172(3):241-6. doi:10.7417/CT.2021.2322.Chandran M, Wong J. Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective. Indian J Endocrinol Metab. 2019;23(4):391-9. doi:10.4103/ijem.IJEM_292_19.Chandran M, Wong J. Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective. Indian J Endocrinol Metab. 2019;23(4):391-9. doi:10.4103/ijem.IJEM_292_19.Goldner W. Cancer-Related Hypercalcemia. J Oncol Pract. 2016;12(5):426-32. doi:10.1200/JOP.2016.011155.Goldner W. Cancer-Related Hypercalcemia. J Oncol Pract. 2016;12(5):426-32. doi:10.1200/JOP.2016.011155.Zagzag J, Hu MI, Fisher SB, et al. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018;68(5):377-86. doi:10.3322/caac.21489.Zagzag J, Hu MI, Fisher SB, et al. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018;68(5):377-86. doi:10.3322/caac.21489.O’Callaghan S, Yau H. Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift. Endocr Connect. 2021;10(1):R13-R24. doi:10.1530/EC-20-0487.O’Callaghan S, Yau H. Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift. Endocr Connect. 2021;10(1):R13-R24. doi:10.1530/EC-20-0487.Pérez-Barrios C, Hernández-Álvarez E, Blanco-Navarro I, et al. Prevalence of hypercalcemia related to hypervitaminosis D in clinical practice. Clin Nutr. 2016;35(6):1354-8. doi:10.1016/j.clnu.2016.02.017.Pérez-Barrios C, Hernández-Álvarez E, Blanco-Navarro I, et al. Prevalence of hypercalcemia related to hypervitaminosis D in clinical practice. Clin Nutr. 2016;35(6):1354-8. doi:10.1016/j.clnu.2016.02.017.Caillet P, Goyer-Joos A, Viprey M, et al. Increase of vitamin D assays prescriptions and associated factors: a population-based cohort study. Sci Rep. 2017;7(1):10361. doi:10.1038/s41598-017-10263-8.Caillet P, Goyer-Joos A, Viprey M, et al. Increase of vitamin D assays prescriptions and associated factors: a population-based cohort study. Sci Rep. 2017;7(1):10361. doi:10.1038/s41598-017-10263-8.Galior K, Grebe S, Singh R. Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports. Nutrients. 2018;10(8):953. doi:10.3390/nu10080953.Galior K, Grebe S, Singh R. Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports. Nutrients. 2018;10(8):953. doi:10.3390/nu10080953.Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016;37(5):521-47. doi:10.1210/er.2016-1070.Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016;37(5):521-47. doi:10.1210/er.2016-1070.Khan AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2004;89:3319-25. doi:10.1210/jc.2003-030908.Khan AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2004;89:3319-25. doi:10.1210/jc.2003-030908.Tournis S, Fakidari E, Dontas I, et al. Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J. Bone Miner. Metab. 2014;32:151-8. doi:10.1007/s00774-013-0473-6.Tournis S, Fakidari E, Dontas I, et al. Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J. Bone Miner. Metab. 2014;32:151-8. doi:10.1007/s00774-013-0473-6.Miyaoka D, Imanishi Y, Kato E, et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine. 2020;69:642-9. doi:10.1007/s12020-020-02401-6.Miyaoka D, Imanishi Y, Kato E, et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine. 2020;69:642-9. doi:10.1007/s12020-020-02401-6.Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2005;90:135-41. doi:10.1210/jc.2004-0842.Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2005;90:135-41. doi:10.1210/jc.2004-0842.Пигарова Е. А., Рожинская Л. Я. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы Эндокринологии. 2016;62(4):60-84. doi:10.14341/probl201662460-84.Pigarova EA, Rozhinskaya LY, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.) doi:10.14341/probl201662460-84.Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: Prospective cohort study. BMJ. 2012;345:e6390. doi:10.1136/bmj.e6390.Paik JM, Curhan GC, Taylor EN. Calcium intake and risk of primary hyperparathyroidism in women: Prospective cohort study. BMJ. 2012;345:e6390. doi:10.1136/bmj.e6390.Hanna RM, Hasnain H, Sangalang MD, et al. Three Patients with Lithium-Associated Hyperparathyroidism: Literature Review Regarding Medical and Surgical Management. Case Rep Nephrol Dial. 2019;9(2):108-18. doi:10.1159/000502399.Hanna RM, Hasnain H, Sangalang MD, et al. Three Patients with Lithium-Associated Hyperparathyroidism: Literature Review Regarding Medical and Surgical Management. Case Rep Nephrol Dial. 2019;9(2):108-18. doi:10.1159/000502399.Bernstein J, Friedman RA. Lithium-associated hyperthyroidism treated with lithium withdrawal: a case report. Am J Psychiatry. 2011;168(4):438-9. doi:10.1176/appi.ajp.2010.10101521.Bernstein J, Friedman RA. Lithium-associated hyperthyroidism treated with lithium withdrawal: a case report. Am J Psychiatry. 2011;168(4):438-9. doi:10.1176/appi.ajp.2010.10101521.Houweling BM, Twigt BA, Regeer EJ, et al. Lithium-geïnduceerde hyperparathy reoïdie [Lithium-induced hyperparathyroidism]. Ned Tijdschr Geneeskd. 2012;156(7):A4091.Houweling BM, Twigt BA, Regeer EJ, et al. Lithium-geïnduceerde hyperparathy reoïdie [Lithium-induced hyperparathyroidism]. Ned Tijdschr Geneeskd. 2012;156(7):A4091.Desai HV, Gandhi K, Sharma M, et al. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther. 2010;17(6):e234-6. doi:10.1097/MJT.0b013e3181c6c21b.Desai HV, Gandhi K, Sharma M, et al. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther. 2010;17(6):e234-6. doi:10.1097/MJT.0b013e3181c6c21b.Tsvetov G, Hirsch D, Shimon I, et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication? J Clin Endocrinol Metab. 2017;102(4):1270-6. doi:10.1210/jc.2016-2481.Tsvetov G, Hirsch D, Shimon I, et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication? J Clin Endocrinol Metab. 2017;102(4):1270-6. doi:10.1210/jc.2016-2481.Robien K, Oppeneer SJ, Kelly JA, et al. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194-208. doi:10.1177/0884533612467824.Robien K, Oppeneer SJ, Kelly JA, et al. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194-208. doi:10.1177/0884533612467824.Rehan MA, Rashid A, Krell K, et al. Calcium Alkali Thiazide Syndrome: What We Need to Know. Cureus. 2020;12(10):e10856. doi:10.7759/cureus.10856.Rehan MA, Rashid A, Krell K, et al. Calcium Alkali Thiazide Syndrome: What We Need to Know. Cureus. 2020;12(10):e10856. doi:10.7759/cureus.10856.Chandler PD, Scott JB, Drake BF, et al. Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D. Am J Med. 2014;127(8):772-8. doi:10.1016/j.amjmed.2014.02.044.Chandler PD, Scott JB, Drake BF, et al. Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D. Am J Med. 2014;127(8):772-8. doi:10.1016/j.amjmed.2014.02.044.Gorvin CM, Hannan FM, Cranston T, et al. Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα11 Mutation. J Bone Miner Res. 2018;33(1):32-41. doi:10.1002/jbmr.3241.Gorvin CM, Hannan FM, Cranston T, et al. Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα11 Mutation. J Bone Miner Res. 2018;33(1):32-41. doi:10.1002/jbmr.3241.Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017;104(7):804-13. doi:10.1002/bjs.10554.Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg. 2017;104(7):804-13. doi:10.1002/bjs.10554.El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507-28. doi:10.1210/clinem/dgac621.El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507-28. doi:10.1210/clinem/dgac621.Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-67. doi:10.1200/JCO.2001.19.2.558.Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-67. doi:10.1200/JCO.2001.19.2.558.Diel IJ, Body JJ, Stopeck AT, et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015;51(11):1467-75. doi:10.1016/j.ejca.2015.04.017.Diel IJ, Body JJ, Stopeck AT, et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015;51(11):1467-75. doi:10.1016/j.ejca.2015.04.017.

The authors declare that there are no conflicts of interest present.